Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
After finishing at $11.41 in the prior trading day, 4D Molecular Therapeutics Inc (NASDAQ: FDMT) closed at $11.32, down -0.79%. In other words, the price has decreased by -$0.79 from its previous closing price. On the day, 0.92 million shares were traded. FDMT stock price reached its highest trading level at $11.59 during the session, while it also had its lowest trading level at $11.0924.
Ratios:
Our goal is to gain a better understanding of FDMT by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.75 and its Current Ratio is at 8.75. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for the company, BMO Capital Markets on January 13, 2025, Downgraded its rating to Market Perform and sets its target price to $15 from $40 previously.
On November 21, 2024, Morgan Stanley started tracking the stock assigning a Underweight rating and target price of $8.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 24 ’25 when Bizily Scott sold 2,678 shares for $12.00 per share. The transaction valued at 32,136 led to the insider holds 3,594 shares of the business.
SCOTT BIZILY bought 1,816 shares of FDMT for $18,160 on Oct 24 ’25. On Oct 16 ’25, another insider, Bizily Scott, who serves as the Chief Legal Officer of the company, sold 1,635 shares for $10.17 each. As a result, the insider received 16,628 and left with 5,188 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FDMT now has a Market Capitalization of 528671936 and an Enterprise Value of 258523920. For the stock, the TTM Price-to-Sale (P/S) ratio is 17622.33 while its Price-to-Book (P/B) ratio in mrq is 1.26. Its current Enterprise Value per Revenue stands at 7834.058 whereas that against EBITDA is -1.198.
Stock Price History:
The Beta on a monthly basis for FDMT is 2.96, which has changed by 0.3983941 over the last 52 weeks, in comparison to a change of 0.19088471 over the same period for the S&P500. Over the past 52 weeks, FDMT has reached a high of $12.34, while it has fallen to a 52-week low of $2.23. The 50-Day Moving Average of the stock is 34.74%, while the 200-Day Moving Average is calculated to be 113.73%.
Shares Statistics:
The stock has traded on average 1.33M shares per day over the past 3-months and 1011470 shares per day over the last 10 days, according to various share statistics. A total of 46.70M shares are outstanding, with a floating share count of 41.39M. Insiders hold about 11.38% of the company’s shares, while institutions hold 81.91% stake in the company. Shares short for FDMT as of 1760486400 were 4219162 with a Short Ratio of 3.18, compared to 1757894400 on 4691697. Therefore, it implies a Short% of Shares Outstanding of 4219162 and a Short% of Float of 9.4.
Earnings Estimates
The performance of 4D Molecular Therapeutics Inc (FDMT) in the stock market is under the watchful eye of 10.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.88, with high estimates of -$0.46 and low estimates of -$1.1.
Analysts are recommending an EPS of between -$3.19 and -$3.98 for the fiscal current year, implying an average EPS of -$3.68. EPS for the following year is -$3.8, with 9.0 analysts recommending between -$2.8 and -$4.76.
